Styles J A, Davies A, Lim C K, De Matteis F, Stanley L A, White I N, Yuan Z X, Smith L L
MRC Toxicology Unit, University of Leicester, UK.
Carcinogenesis. 1994 Jan;15(1):5-9. doi: 10.1093/carcin/15.1.5.
The clastogenicity of tamoxifen and toremifene was tested in six human lymphoblastoid cell lines each expressing increased monooxygenase activity associated with a specific transfected human cytochrome P450 cDNA (CYP1A1, CYP1A2, CYP2D6, CYP2E1 or CYP3A4). The chemicals were also tested in a cell line (MCL-5) expressing elevated native CYP1A1 and containing transfected CYP1A2, CYP2A6, CYP2E1 and CYP3A4 and epoxide hydrolase, and in a cell line containing only the viral vector (Ho1). Dose-related increases in micronuclei were observed when cells expressing 2E1, 3A4, 2D6 or MCL-5 cells were exposed to tamoxifen. The positive responses in the cell lines were in the order MCL-5 > 2E1 > 3A4 > 2D6. Toremifene also gave positive results with 2E1, 3A4 and MCL-5 cells, although the responses were less marked and the positive effects required higher doses than with tamoxifen. A synthesized epoxide of tamoxifen was also tested in these cell lines and produced similar increases in the incidences of micronucleated cells. The increases in the responses observed with the epoxide were greater than with tamoxifen or toremifene. The P450 isoenzyme activities in these cells were in a range similar to those of human tumour-derived cell lines. Microsomes (1A1, 2A2, 2A6, 2B6, 2E1, 3A4 and 2D6) from these cells all metabolized tamoxifen. The major metabolite detected by HPLC was N-desmethyltamoxifen, and 4-hydroxytamoxifen was also detected in cells with cytochrome P450 2E1 and 2D6. These results are consistent with the following conclusions. (1) Tamoxifen requires metabolic activation to DNA-reactive species by specific CYP monooxygenases in order to exert its genotoxic effects. (2) The positive clastogenic effects elicited in lymphoblastoid cells by tamoxifen epoxide suggest that the genotoxic (and possibly the carcinogenic) effects of tamoxifen may be due to one or more epoxide metabolites that are generated intracellularly, probably in close proximity to the nucleus. (3) Tamoxifen is more genotoxic than toremifene.
在六种人淋巴母细胞系中测试了他莫昔芬和托瑞米芬的致断裂性,每种细胞系均表达与特定转染的人细胞色素P450 cDNA(CYP1A1、CYP1A2、CYP2D6、CYP2E1或CYP3A4)相关的单加氧酶活性增加。还在表达升高的天然CYP1A1并含有转染的CYP1A2、CYP2A6、CYP2E1、CYP3A4和环氧化物水解酶的细胞系(MCL-5)以及仅含有病毒载体的细胞系(Ho1)中测试了这些化学物质。当表达2E1、3A4、2D6的细胞或MCL-5细胞暴露于他莫昔芬时,观察到微核呈剂量相关增加。细胞系中的阳性反应顺序为MCL-5>2E1>3A4>2D6。托瑞米芬在2E1、3A4和MCL-5细胞中也给出了阳性结果,尽管反应不太明显,且产生阳性效应所需的剂量比他莫昔芬更高。还在这些细胞系中测试了他莫昔芬的一种合成环氧化物,其产生的微核化细胞发生率也有类似增加。观察到环氧化物引起的反应增加大于他莫昔芬或托瑞米芬。这些细胞中的P450同工酶活性范围与人肿瘤衍生细胞系的活性范围相似。这些细胞的微粒体(1A1、2A2、2A6、2B6、2E1、3A4和2D6)均能代谢他莫昔芬。通过高效液相色谱法检测到的主要代谢产物是N-去甲基他莫昔芬,在具有细胞色素P450 2E1和2D6的细胞中也检测到了4-羟基他莫昔芬。这些结果与以下结论一致。(1)他莫昔芬需要通过特定的CYP单加氧酶代谢活化为具有DNA反应性的物质,才能发挥其遗传毒性作用。(2)他莫昔芬环氧化物在淋巴母细胞中引起的阳性致断裂效应表明,他莫昔芬的遗传毒性(可能还有致癌性)作用可能归因于一种或多种在细胞内产生的环氧化物代谢产物,这些代谢产物可能在细胞核附近产生。(3)他莫昔芬的遗传毒性比托瑞米芬更强。